tag@treatmentactiongroup.org

Access to Medicines

New Report Urges Action to Ensure Sustainable, Affordable Supply of Key Vaccine Adjuvants for Global Health Use

  • Dorrit Walsh

Behind many lifesaving vaccines is a fragile supply chain that few people ever see. This new TAG report examines how weaknesses in the production and supply of key vaccine adjuvants (an ingredient that enhances the immune response) can create bottlenecks that threaten global access to vaccines, underscoring the importance of greater market transparency, security, and competitiveness among governments, funders, and pharmaceutical companies.

Read more

TAG and ANEA Coalition Condemn Proposed $2 Billion in Cuts to HIV Funding

  • Dorrit Walsh

Treatment Action Group and ANEA Coalition strongly condemn the House Labor, Health and Human Services proposed $2 billion in federal cuts to domestic HIV programs, including plans that would dismantle the CDC’s Division of HIV Prevention and slash $535 million from the Ryan White HIV/AIDS Program.

Read more

Gilead Deal to Expand Access to Lenacapavir for PrEP Falls Short

  • Dorrit Walsh

TAG recognizes Gilead Science’s announcement that it has issued six voluntary licenses to produce generic lenacapavir for distribution within 120 high HIV burden countries as a first step toward broadening access to this potent preventive drug for millions of people at risk of HIV.

Read more

1/4/6×24 Mid-Campaign Report Launch Webinar

  • Dorrit Walsh

On March 27, 2024, the 1/4/6x24 Campaign and the Stop TB Partnership co-hosted a webinar to launch the Campaign’s new report: Getting Better Faster: Delivering on the Promise of New TB Treatments.

Read more
Back To Top